AMGN Stock Recent News

In the latest trading session, Amgen (AMGN) closed at $295.18, marking a -1.73% move from the previous day.

Generating passive income is great for investors, and holding dividend-paying stocks is an excellent way to do that. However, not all corporations that pay dividends will be attractive to income seekers.

Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid, offering defensive characteristics, capital preservation, and yield over high-growth potential. The diversified product base and growing biosimilars segment reduce concentration and patent cliff risks, supporting Amgen's stability as a portfolio anchor. Biosimilars face execution, pricing, and demand risks, but continued strong growth could offset upcoming revenue losses from key patent expirations.

Amgen (AMGN) closed the most recent trading day at $297, moving +1.38% from the previous trading session.

The latest trading day saw Amgen (AMGN) settling at $296.85, representing a +2.18% change from its previous close.

The Investment Committee give you their top stocks to watch for the second half.

There are a lot of healthcare companies that are investing in GLP-1 weight loss drugs. Today, the leaders in that space are Eli Lilly and Novo Nordisk.

Tech stocks lagged after a very strong first half of the year, while healthcare led the way.

Following quite encouraging news from the laboratory on Monday, Amgen (AMGN 4.07%) was something of a stock market favorite the following day. Its shares closed the trading session more than 4% higher on the back of both that sentiment and a pair of optimistic analyst takes on the latest development.

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.